| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03992443 2021-004026-30 Details | 2022-04-15 Interventional | 3 | 0 | Reteplase Restoration of … | Chiesi business decision - | |||
| NCT04272333 Details | 2022-04-14 Interventional | 1 | 1 | Nivolumab Squamous Cell C… HNSCC | Partner Termination - | |||
| NCT03191526 Details | 2022-04-14 Interventional | 3 | 66 | Mogamulizumab Bone Marrow Dis… Paraparesis, Tr… Spinal Cord Dis… HTLV-1 Associat… | Due to not achieving the primary outcome. - | |||
| NCT03041701 Details | 2022-04-14 Interventional | 1/2 | 14 | Dasatinib Rhabdomyosarcom… Rhabdomyosarcom… Rhabdomyosarcom… | The pharmaceutical company discontinued availability of the drug and we were forced to close
the study before phase II was completed. Only one participant was enrolled on phase II. - | |||
| NCT03021083 Details | 2022-04-14 Interventional | 4 | 0 | Fentanyl Spinal Injuries Spinal Injury | Contract not reached with sponsor - | |||
| NCT02945813 2016-003599-39 Details | 2022-04-14 Interventional | 2 | 112 | Metformin Prostatic Neopl… Prostate Cancer | Trial was prematurely closed for accrual by the SAKK Board and the follow-up period shortened
to one year after last RT fraction of the last patient - | |||
| NCT01766128 Details | 2022-04-14 Interventional | 2/3 | 0 | Zonisamide Parkinson Disea… | Practical problems - | |||
| NCT04421664 Details | 2022-04-13 Interventional | 3 | [2 Refs] | 70 | Hydroxychloroqu… COVID-19 Communicable Di… Coronavirus Inf… Infections Severe Acute Re… Corona Virus In… Coronavirus SARS-CoV Infect… | Request of Health Canada after publication of https://doi.org/10.7326/M20-4207 - | ||
| NCT05295394 Details | 2022-04-12 Interventional | 4 | 0 | Dolutegravir Lamivudine HIV-1 Infection | Low recruitment, We did not find participants with the M184V mutation , inclusion criteria ,
throughout 230 resistance tests carried out - | |||
| NCT04965272 Details | 2022-04-12 Interventional | 2 | 0 | Cariprazine Anxiety Disorde… Generalized Anx… | Strategic Decision - | |||
| NCT04336748 Details | 2022-04-12 Interventional | 3 | 0 | Hydroxychloroqu… Virus Diseases Healthcare Work… Infection Viral Prophylaxis Sars-CoV2 | Not feasible - | |||
| NCT03950037 Details | 2022-04-12 Interventional | 2 | 0 | Albendazole Cysticercosis Neurocysticerco… Taeniasis Subarachnoid Ne… | Unable to complete due to SARS-CoV-2 pandemic - | |||
| NCT03434366 Details | 2022-04-12 Interventional | 2 | - | Dexmedetomidine Ketamine Autism Spectrum… Autistic Disord… Child Developme… | The effects are not good - | |||
| NCT00286169 Details | 2022-04-12 Interventional | 3 | - | Amrubicin Lung Neoplasms Small Cell Lung… Small-cell Lung… | - - | |||
| NCT03707028 Details | 2022-04-11 Interventional | 1/2 | 12 | Apatinib Paclitaxel Adenocarcinoma Gastric Cancer Gastroesophagea… | Terminated after completion of Part 1 due to a change in research plan. - | |||
| NCT03593213 NCT04519099 2017-000818-34 Details | 2022-04-11 Interventional | 3 | 587 | Cariprazine Schizophrenia | FDA Released Allergan from this post marketing requirement - | |||
| NCT03532022 Details | 2022-04-08 Interventional | 3 | 0 | Dexamethasone Hydrocortisone Hydrocortisone … Hydrocortisone … Hydrocortisone … Prednisolone Prednisone Adrenal Hyperpl… Adrenogenital S… Hyperplasia Congenital Adre… | Protocol re-design required following EU Phase III results - | |||
| NCT02384850 Details | 2022-04-08 Interventional | 1 | 10 | Fluorouracil Folic Acid Leucovorin Levoleucovorin Oxaliplatin Colorectal Neop… Colorectal Neop… | - - | |||
| NCT04471714 Details | 2022-04-07 Interventional | 2 | 0 | Baclofen Muscle Spastici… Spinal Cord Inj… Spasticity, Mus… | Study recruitment was halted due to restrictions and we have decided to not pursue it further. - | |||
| NCT04246619 2017-004341-24 Details | 2022-04-07 Interventional | 4 | 254 | Duloxetine Hydr… Pregabalin Diabetic Neurop… Pain Peripheral Nerv… Painful Diabeti… | The statistical analysis will still provide relevant results with the same statistical power as
initially planned.COVID-19 pandemic prolonged the recruiting period and consequently affected
the costs of the clinical trial. - |